The microbiome in inflammatory bowel diseases: from pathogenesis to therapy

Abstract

Inflammatory bowel disease (IBD) has become a global disease with accelerating incidence worldwide in the 21st century while its accurate etiology remains unclear. In the past decade, gut microbiota dysbiosis has consistently been associated with IBD. Although many IBDassociated dysbiosis have not been proven to be a cause or an effect of IBD, it is often hypothesized that at least some of alteration in microbiome is protective or causative. In this article, we selectively reviewed the hypothesis supported by both association studies in human and pathogenesis studies in biological models. Specifically, we reviewed the potential protective bacterial pathways and species against IBD, as well as the potential causative bacterial pathways and species of IBD. We also reviewed the potential roles of some members of mycobiome and virome in IBD. Lastly, we covered the current status of therapeutic approaches targeting microbiome, which is a promising strategy to alleviate and cure this inflammatory disease.

Key words： inflammatory bowel disease; pathogenesis; etiology; microbiome; dysbiosis; therapy

References

1 Abraham BP, Quigley EMM (2017) Probiotics in inflammatory bowel disease. Gastroenterol Clin N Am 46:769–782

2 Agus A,Planchais J, Sokol H (2018) Gut microbiota regulation of tryptophan metabolism in health and disease. Cell Host Microbe 23:716–724

3 Akram W, Garud N, Joshi R (2019) Role of inulin as prebiotics on inflammatory bowel disease. Drug Discov Ther 13:1–8

4 Alhagamhmad MH, Day AS, Lemberg DA, Leach ST (2016) An overview of the bacterial contribution to Crohn disease pathogenesis. J Med Microbiol 65:1049–1059

5 An D, Oh SF, Olszak T, Neves JF, Avci FY, Erturk-Hasdemir D, Lu X, Zeissig S, Blumberg RS, Kasper DL (2014) Sphingolipids from a symbiotic microbe regulate homeostasis of host intestinal natural killer T cells. Cell 156:123–133

6 Ansaldo E, Slayden LC, Ching KL, Koch MA, Wolf NK, Plichta DR, Brown EM, Graham DB, Xavier RJ, Moon JJ (2019) Akkermansia muciniphila induces intestinal adaptive immune responses during homeostasis. Science 364:1179–1184

7 Arthur JC, Perez-Chanona E, Muhlbauer M, Tomkovich S, Uronis JM, Fan TJ, Campbell BJ, Abujamel T, Dogan B, Rogers AB (2012) Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 338:120–123

8 Atherly T, Mosher C, Wang C,Hostetter J,Proctor A, Brand MW, Phillips GJ, Wannemuehler M, Jergens AE (2016) Helicobacter bilis infection alters mucosal bacteria and modulates colitis development in defined microbiota mice. Inflamm Bowel Dis 22:2571–2581

9 Barnett MP, McNabb WC, Cookson AL, Zhu S, Davy M, Knoch B, Nones K, Hodgkinson AJ, Roy NC (2010) Changes in colon gene expression associated with increased colon inflammation in interleukin-10 gene-deficient mice inoculated with Enterococcus species. BMC Immunol 11:39

10 Barnich N, Carvalho FA, Glasser AL, Darcha C, Jantscheff P, Allez M, Peeters H, Bommelaer G, Desreumaux P,Colombel JF (2007) CEACAM6 acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa colonization in Crohn disease. J Clin Investig 117:1566–1574

11 Bell A, Brunt J, Crost E, Vaux L, Nepravishta R, Owen CD, Latousakis D, Xiao A, Li W, Chen X (2019) Elucidation of a sialic acid metabolism pathway in mucus-foraging Ruminococcus gnavus unravels mechanisms of bacterial adaptation to the gut. Nat Microbiol 4:2393–2404

12 Bian X, Wu W, Yang L, Lv L, Wang Q, Li Y, Ye J, Fang D, Wu J, Jiang X (2019) Administration of Akkermansia muciniphila ameliorates dextran sulfate sodium-induced ulcerative colitis in mice. Front Microbiol 10:2259

13 Bibiloni R, Fedorak RN, Tannock GW, Madsen KL, Gionchetti P, Campieri M, De Simone C, Sartor RB (2005) VSL#3 probioticmixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 100:1539–1546

14 Bjarnason I, Sission G,Hayee B (2019) A randomised, double-blind, placebo-controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn’s disease. Inflammopharmacology 27:465–473

15 Blandford LE, Johnston EL, Sanderson JD, Wade WG, Lax AJ (2019) Promoter orientation of the immunomodulatory Bacteroides fragilis capsular polysaccharide A (PSA) is off in individuals with inflammatory bowel disease (IBD). Gut Microbes 10:569–577

16 Breban M, Tap J, Leboime A, Said-Nahal R, Langella P, Chiocchia G,Furet JP, Sokol H (2017) Faecal microbiota study reveals specific dysbiosis in spondyloarthritis. Ann Rheum Dis 76:1614–1622

17 Bringer MA, Glasser AL, Tung CH, Meresse S,Darfeuille-Michaud A (2006) The Crohn’s disease-associated adherent-invasive Escherichia coli strain LF82 replicates in mature phagolysosomes within J774 macrophages. Cell Microbiol 8:471–484

18 Burrello C, Garavaglia F, Cribiu FM, Ercoli G, Lopez G, Troisi J, Colucci A, Guglietta S, Carloni S, Guglielmetti S (2018) Therapeutic faecal microbiota transplantation controls intestinal inflammation through IL10 secretion by immune cells. Nat Commun 9:5184

19 Cammarota G,Ianiro G, Tilg H, Rajilic-Stojanovic M,Kump P,Satokari R, Sokol H, Arkkila P, Pintus C,Hart A (2017) European consensus conference on faecal microbiota transplantation in clinical practice. Gut 66:569–580

20 Cammarota G, Ianiro G, Kelly CR, Mullish BH, Allegretti JR, Kassam Z, Putignani L, Fischer M, Keller JJ, Costello SP (2019) International consensus conference on stool banking for faecal microbiota transplantation in clinical practice. Gut 68:2111–2121

21 Cao X(2017) Intestinal inflammation induced by oral bacteria. Science 358:308–309

22 Castano-Rodriguez N, Kaakoush NO, Lee WS, Mitchell HM (2017) Dual role of Helicobacter and Campylobacter species in IBD: a systematic review and meta-analysis. Gut 66:235–249

23 Chai JN, Peng Y, Rengarajan S, Solomon BD, Ai TL, Shen Z, Perry JSA, Knoop KA, Tanoue T, Narushima S (2017) Helicobacter species are potent drivers of colonic T cell responses in homeostasis and inflammation. Sci Immunol 2(13):eaal5068

24 Chehoud C,Albenberg LG, Judge C,Hoffmann C, Grunberg S, Bittinger K,Baldassano RN, Lewis JD, Bushman FD, Wu GD (2015) Fungal signature in the gut microbiota of pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 21:1948–1956

25 Chiaro TR, Soto R, Zac Stephens W, Kubinak JL, Petersen C, Gogokhia L, Bell R, Delgado JC, Cox J,Voth W (2017) A member of the gut mycobiota modulates host purine metabolism exacerbating colitis in mice. Sci Transl Med 9(380):eaaf9044

26 Chua HH, Chou HC, Tung YL, Chiang BL, Liao CC, Liu HH, Ni YH (2018) Intestinal dysbiosis featuring abundance of Ruminococcus gnavus associates with allergic diseases in infants. Gastroenterology 154:154–167

27 Chung L, Thiele Orberg E, Geis AL, Chan JL, Fu K, DeStefano Shields CE, Dejea CM, Fathi P, Chen J, Finard BB (2018) Bacteroides fragilis toxin coordinates a pro-carcinogenic inflammatory cascade via targeting of colonic epithelial cells. Cell Host Microbe 23(203–214):e205

28 Clooney AG, Sutton TDS, Shkoporov AN, Holohan RK, Daly KM, O’Regan O,Ryan FJ, Draper LA, Plevy SE, Ross RP (2019) Whole-virome analysis sheds light on viral dark matter in inflammatory bowel disease. Cell Host Microbe 26:764–778.e765

29 Coker OO, Nakatsu G,Dai RZ, Wu WKK, Wong SH, Ng SC, Chan FKL, Sung JJY, Yu J(2019) Enteric fungal microbiota dysbiosis and ecological alterations in colorectal cancer. Gut 68:654–662

30 Colombel JF, Shin A, Gibson PR (2019) AGA clinical practice update on functional gastrointestinal symptoms in patients with inflammatory bowel disease: expert review. Clin Gastroenterol Hepatol 17:380–390.e381

31 Connors J,Dunn KA, Allott J,Bandsma R, Rashid M, Otley AR, Bielawski JP, Van Limbergen J (2019) The relationship between fecal bile acids and microbiome community structure in pediatric Crohn’s disease . ISME J 14:702–713

32 Cui B, Feng Q, Wang H, Wang M, Peng Z, Li P,Huang G, Liu Z, Wu P, Fan Z (2015) Fecal microbiota transplantation through mid-gut for refractory Crohn’s disease: safety, feasibility, and efficacy trial results. J Gastroenterol Hepatol 30:51–58

33 Darfeuille-Michaud A (2002) Adherent-invasive Escherichia coli: a putative new E. coli pathotype associated with Crohn’s disease. Int J Med Microbiol 292:185–193

34 Darfeuille-Michaud A, Boudeau J, Bulois P, Neut C,Glasser AL, Barnich N, Bringer MA, Swidsinski A, Beaugerie L, Colombel JF (2004) High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn’s disease. Gastroenterology 127:412–421

35 De Hertogh G, Aerssens J, Geboes KP, Geboes K (2008) Evidence for the involvement of infectious agents in the pathogenesis of Crohn’s disease. World J Gastroenterol 14:845–852

36 Dedrick RM, Guerrero-Bustamante CA, Garlena RA, Russell DA, Ford K, Harris K, Gilmour KC, Soothill J,Jacobs-Sera D, Schooley RT (2019) Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat Med 25:730–733

37 Dejea CM, Fathi P, Craig JM, Boleij A, Taddese R, Geis AL, Wu X, DeStefano Shields CE, Hechenbleikner EM, Huso DL (2018) Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science 359:592–597

38 Derwa Y, Gracie DJ, Hamlin PJ, Ford AC (2017) Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease. Aliment Pharmacol Ther 46:389–400

39 Dickson I (2018) Gut microbiota: oral bacteria: a cause of IBD? Nat Rev Gastroenterol Hepatol 15:4–5

40 Dodd D, Spitzer MH, Van Treuren W, Merrill BD, Hryckowian AJ, Higginbottom SK, Le A, Cowan TM, Nolan GP, Fischbach MA (2017) A gut bacterial pathway metabolizes aromatic amino acids into nine circulating metabolites. Nature 551:648–652

41 Draper LA, Ryan FJ, Smith MK, Jalanka J,Mattila E, Arkkila PA, Ross RP, Satokari R, Hill C (2018) Long-term colonisation with donor bacteriophages following successful faecal microbial transplantation. Microbiome 6:220

42 Duan Y, Llorente C, Lang S, Brandl K, Chu H, Jiang L, White RC, Clarke TH, Nguyen K, Torralba M (2019) Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature 575:505–511

43 Duboc H, Rajca S, Rainteau D,Benarous D,Maubert MA, Quervain E, Thomas G, Barbu V, Humbert L, Despras G (2013) Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut 62:531–539

44 Duerkop BA, Kleiner M, Paez-Espino D, Zhu W, Bushnell B, Hassell B,Winter SE, Kyrpides NC, Hooper LV (2018) Murine colitis reveals a disease-associated bacteriophage community. Nat Microbiol 3:1023–1031

45 Eaton K, Pirani A, Snitkin ES, Reproducibility Project: Cancer B, Iorns E,Tsui R, Denis A, Perfito N, Errington TM, Iorns E (2018). Replication Study: intestinal inflammation targets cancerinducing activity of the microbiota. Elife 7:e34364.

46 el-Omar E,Penman I, Cruikshank G, Dover S, Banerjee S,Williams C, McColl KE (1994) Low prevalence of Helicobacter pylori in inflammatory bowel disease: association with sulphasalazine. Gut 35:1385–1388

47 Erickson AR, Cantarel BL, Lamendella R, Darzi Y,Mongodin EF, Pan C, Shah M, Halfvarson J, Tysk C,Henrissat B (2012) Integrated metagenomics/metaproteomics reveals human hostmicrobiota signatures of Crohn’s disease. PLoS ONE 7:e49138

48 Fedorak RN, Feagan BG, Hotte N, Leddin D, Dieleman LA, Petrunia DM, Enns R, Bitton A, Chiba N, Pare P (2015) The probiotic VSL#3 has anti-inflammatory effects and could reduce endoscopic recurrence after surgery for Crohn’s disease. Clin Gastroenterol Hepatol 13:928–935.e922

49 Franzosa EA, Sirota-Madi A, Avila-Pacheco J, Fornelos N, Haiser HJ, Reinker S, Vatanen T, Hall AB, Mallick H, McIver LJ (2019) Gut microbiome structure and metabolic activity in inflammatory bowel disease. Nat Microbiol 4:293–305

50 Freedman SB, Williamson-Urquhart S,Farion KJ, Gouin S, Willan AR, Poonai N, Hurley K, Sherman PM, Finkelstein Y, Lee BE(2018) Multicenter trial of a combination probiotic for children with gastroenteritis. N Engl J Med 379:2015–2026

51 Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, Nakanishi Y, Uetake C, Kato K, Kato T (2013) Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504:446–450

52 Galtier M, De Sordi L, Sivignon A, de Vallee A, Maura D, Neut C, Rahmouni O, Wannerberger K, Darfeuille-Michaud A, Desreumaux P (2017) Bacteriophages targeting adherent invasive Escherichia coli strains as a promising new treatment for Crohn’s disease. J Crohns Colitis 11:840–847

53 Garrett WS (2019) The gut microbiota and colon cancer. Science 364:1133–1135

54 Garrett WS, Gallini CA, Yatsunenko T, Michaud M, DuBois A, Delaney ML, Punit S, Karlsson M, Bry L,Glickman JN (2010) Enterobacteriaceae act in concert with the gut microbiota to induce spontaneous and maternally transmitted colitis. Cell Host Microbe 8:292–300

55 Gibson GR, Hutkins R, Sanders ME, Prescott SL, Reimer RA, Salminen SJ, Scott K, Stanton C,Swanson KS, Cani PD (2017) Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol 14:491–502

56 Gogokhia L,Buhrke K, Bell R, Hoffman B, Brown DG, Hanke-Gogokhia C, Ajami NJ, Wong MC, Ghazaryan A, Valentine JF (2019) Expansion of bacteriophages is linked to aggravated intestinal inflammation and colitis. Cell Host Microbe 25:285–299. e288

57 Hall AB, Yassour M, Sauk J,Garner A, Jiang X, Arthur T, Lagoudas GK, Vatanen T, Fornelos N, Wilson R (2017) A novel Ruminococcus gnavus clade enriched in inflammatory bowel disease patients. Genome Med 9:103

58 Hamilton MJ, Weingarden AR, Sadowsky MJ, Khoruts A (2012) Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol 107:761–767

59 Hang S, Paik D, Yao L, Kim E, Trinath J, Lu J, Ha S, Nelson BN, Kelly SP, Wu L (2019) Bile acid metabolites control TH17 and Treg cell differentiation. Nature 576:143–148

60 Hedin C, van der Gast CJ, Rogers GB, Cuthbertson L, McCartney S, Stagg AJ, Lindsay JO, Whelan K (2016) Siblings of patients with Crohn’s disease exhibit a biologically relevant dysbiosis in mucosal microbial metacommunities. Gut 65:944–953

61 Henke MT, Kenny DJ, Cassilly CD, Vlamakis H, Xavier RJ, Clardy J (2019) Ruminococcus gnavus, a member of the human gut microbiome associated with Crohn’s disease, produces an inflammatory polysaccharide. Proc Natl Acad Sci USA 116:12672–12677

62 Hill C,Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L,Canani RB, Flint HJ, Salminen S (2014) Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 11:506–514

63 Hvas CL, Dahl Jørgensen SM, Jørgensen SRP, Storgaard M, Lemming L, Hansen MM, Erikstrup C, Dahlerup JF (2019) Fecal microbiota transplantation is superior to fidaxomicin for treatment of recurrent Clostridium difficile infection. Gastroenterology 156:1324–1332.e1323

64 Iliev ID, Funari VA, Taylor KD, Nguyen Q, Reyes CN, Strom SP, Brown J, Becker CA, Fleshner PR, Dubinsky M (2012) Interactions between commensal fungi and the C-type lectin receptor Dectin-1 influence colitis. Science 336:1314–1317

65 Imhann F, Vich Vila A, Bonder MJ, Fu J, Gevers D, Visschedijk MC, Spekhorst LM, Alberts R, Franke L, van Dullemen HM (2018) Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease. Gut 67:108–119

66 Jergens AE, Wilson-Welder JH, Dorn A, Henderson A, Liu Z, Evans RB, Hostetter J,Wannemuehler MJ (2007) Helicobacter bilis triggers persistent immune reactivity to antigens derived from the commensal bacteria in gnotobiotic C3H/HeN mice. Gut 56:934–940

67 Joossens M, Huys G, Cnockaert M, De Preter V, Verbeke K, Rutgeerts P,Vandamme P, Vermeire S(2011) Dysbiosis of the faecal microbiota in patients with Crohn’s disease and their unaffected relatives. Gut 60:631–637

68 Kalischuk LD, Buret AG (2010) A role for Campylobacter jejuniinduced enteritis in inflammatory bowel disease? Am J Physiol Gastrointest Liver Physiol 298:29

69 Khoruts A, Sadowsky MJ (2016) Understanding the mechanisms of faecal microbiota transplantation. Nat Rev Gastroenterol Hepatol 13:508–516

70 Khoruts A, Rank KM, Newman KM, Viskocil K, Vaughn BP, Hamilton MJ, Sadowsky MJ (2016) Inflammatory bowel disease affects the outcome of fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol 14:1433–1438

71 Kim MH, Kang SG, Park JH, Yanagisawa M, Kim CH (2013) Shortchain fatty acids activate GPR41 and GPR43 on intestinal epithelial cells to promote inflammatory responses in mice. Gastroenterology 145(396–406):e391–e310

72 Kirk KF, Nielsen HL, Thorlacius-Ussing O, Nielsen H(2016) Optimized cultivation of Campylobacter concisus from gut mucosal biopsies in inflammatory bowel disease. Gut Pathog 8:27

73 Kostic AD, Xavier RJ, Gevers D (2014) The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology 146:1489–1499

74 Kotlowski R, Bernstein CN, Sepehri S,Krause DO (2007) High prevalence of Escherichia coli belonging to the B2+D phylogenetic group in inflammatory bowel disease. Gut 56:669–675

75 Kruis W, Fric P, Pokrotnieks J, Lukas M, Fixa B, Kascak M, Kamm MA, Weismueller J, Beglinger C,Stolte M (2004) Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53:1617–1623

76 Kullberg MC, Rothfuchs AG, Jankovic D,Caspar P, Wynn TA, Gorelick PL, Cheever AW, Sher A (2001) Helicobacter hepaticusinduced colitis in interleukin-10-deficient mice: cytokine requirements for the induction and maintenance of intestinal inflammation. Infect Immun 69:4232–4241

77 Kullberg MC, Jankovic D, Feng CG, Hue S, Gorelick PL, McKenzie BS, Cua DJ, Powrie F, Cheever AW, Maloy KJ (2006) IL-23 plays a key role in Helicobacter hepaticus-induced T celldependent colitis. J Exp Med 203:2485–2494

78 Laharie D, Asencio C, Asselineau J,Bulois P, Bourreille A, Moreau J, Bonjean P, Lamarque D, Pariente A, Soule JC (2009) Association between entero-hepatic Helicobacter species and Crohn’s disease: a prospective cross-sectional study. Aliment Pharmacol Ther 30:283–293

79 Lam S, Zuo T, Ho M, Chan FKL, Chan PKS, Ng SC (2019) Review article: fungal alterations in inflammatory bowel diseases. Aliment Pharmacol Ther 50:1159–1171

80 Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B,Lomer MCE, Parkes GC, Selinger C (2019) British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 68:s1–s106

81 LaMont JT (2018) Probiotics for children with gastroenteritis. N Engl J Med 379:2076–2077

82 Levy M, Thaiss CA, Zeevi D, Dohnalova L, Zilberman-Schapira G, Mahdi JA, David E, Savidor A, Korem T, Herzig Y (2015) Microbiota-modulated metabolites shape the intestinal microenvironment by regulating NLRP6 inflammasome signaling. Cell 163:1428–1443

83 Li Q, Wang C, Tang C, He Q, Li N, Li J (2014) Dysbiosis of gut fungal microbiota is associated with mucosal inflammation in Crohn’s disease. J Clin Gastroenterol 48:513–523

84 Li XV, Leonardi I, Iliev ID (2019) Gut mycobiota in immunity and inflammatory disease. Immunity 50:1365–1379

85 Limon JJ, Tang J, Li D, Wolf AJ, Michelsen KS, Funari V, Gargus M, Nguyen C, Sharma P, Maymi VI (2019) Malassezia is associated with Crohn’s disease and exacerbates colitis in mouse models. Cell Host Microbe 25:377–388.e376

86 Liu Z, Ramer-Tait AE, Henderson AL, Demirkale CY, Nettleton D, Wang C,Hostetter JM, Jergens AE, Wannemuehler MJ (2011) Helicobacter bilis colonization enhances susceptibility to Typhlocolitis following an inflammatory trigger. Dig Dis Sci 56:2838–2848

87 Lloyd-Price J,Arze C, Ananthakrishnan AN, Schirmer M, Avila-Pacheco J,Poon TW, Andrews E, Ajami NJ, Bonham KS, Brislawn CJ (2019) Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature 569:655–662

88 Lo Presti A, Zorzi F, Del Chierico F, Altomare A, Cocca S, Avola A, De Biasio F,Russo A, Cella E, Reddel S(2019) Fecal and mucosal microbiota profiling in irritable bowel syndrome and inflammatory bowel disease. Front Microbiol 10:1655

89 Lynch SV, Pedersen O (2016) The human intestinal microbiome in health and disease. N Engl J Med 375:2369–2379

90 Machiels K, Joossens M, Sabino J, De Preter V,Arijs I, Eeckhaut V, Ballet V, Claes K, Van Immerseel F, Verbeke K (2014) A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut 63:1275–1283

91 Machiels K, Sabino J, Vandermosten L,Joossens M, Arijs I, de Bruyn M, Eeckhaut V,Van Assche G, Ferrante M, Verhaegen J (2017) Specific members of the predominant gut microbiota predict pouchitis following colectomy and IPAA in UC. Gut 66:79–88

92 Mahendran V, Riordan SM, Grimm MC, Tran TA, Major J, Kaakoush NO, Mitchell H, Zhang L (2011) Prevalence of Campylobacter species in adult Crohn’s disease and the preferential colonization sites of Campylobacter species in the human intestine. PLoS ONE 6:e25417

93 Mahendran V, Liu F, Riordan SM, Grimm MC, Tanaka MM, Zhang L (2016) Examination of the effects of Campylobacter concisus zonula occludens toxin on intestinal epithelial cells and macrophages. Gut Pathog 8:18

94 Man SM, Kaakoush NO, Leach ST, Nahidi L, Lu HK, Norman J,Day AS, Zhang L, Mitchell HM (2010) Host attachment, invasion, and stimulation of proinflammatory cytokines by Campylobacter concisus and other non-Campylobacter jejuni Campylobacter species. J Infect Dis 202:1855–1865

95 Mar JS, LaMere BJ, Lin DL, Levan S, Nazareth M, Mahadevan U,Lynch SV (2016) Disease severity and immune activity relate to distinct interkingdom gut microbiome states in ethnically distinct ulcerative colitis patients. mBio.https://doi.org/10.1128/mBio.01072-16

96 Martin HM, Campbell BJ, Hart CA, Mpofu C, Nayar M, Singh R, Englyst H, Williams HF, Rhodes JM (2004) Enhanced Escherichia coli adherence and invasion in Crohn’s disease and colon cancer. Gastroenterology 127:80–93

97 Martin R, Miquel S, Benevides L, Bridonneau C,Robert V,Hudault S, Chain F, Berteau O, Azevedo V, Chatel JM (2017) Functional characterization of novel Faecalibacterium prausnitzii strains isolated from healthy volunteers: a step forward in the use of F. prausnitzii as a next-generation probiotic. Front Microbiol 8:1226

98 Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL (2005) An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell 122:107–118

99 Mazmanian SK, Round JL, Kasper DL (2008) A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 453:620–625

100 McCallin S, Alam Sarker S, Barretto C, Sultana S, Berger B, Huq S,Krause L, Bibiloni R,Schmitt B, Reuteler G (2013) Safety analysis of a Russian phage cocktail: from metagenomic analysis to oral application in healthy human subjects. Virology 443:187–196

101 Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN, Staiano A (2009) Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol 104:437–443

102 Moayyedi P, Surette MG, Kim PT, Libertucci J, Wolfe M, Onischi C, Armstrong D, Marshall JK, Kassam Z, Reinisch W (2015) Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 149:102–109.e106

103 Morgan XC, Tickle TL, Sokol H,Gevers D,Devaney KL, Ward DV, Reyes JA, Shah SA, LeLeiko N, Snapper SB (2012) Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol 13:R79

104 Mukhopadhya I, Thomson JM, Hansen R, Berry SH, El-Omar EM,Hold GL (2011) Detection of Campylobacter concisus and other Campylobacter species in colonic biopsies from adults with ulcerative colitis. PLoS ONE 6:e21490

105 Mylonaki M, Rayment NB, Rampton DS, Hudspith BN, Brostoff J (2005) Molecular characterization of rectal mucosa-associated bacterial flora in inflammatory bowel disease. Inflamm Bowel Dis 11:481–487

106 Nattramilarasu PK, Bucker R, Lobo de Sa FD, Fromm A, Nagel O, Lee IM, Butkevych E, Mousavi S, Genger C, Klove S (2020) Campylobacter concisus impairs sodium absorption in colonic epithelium via ENaC dysfunction and claudin-8 disruption. Int J Mol Sci 21(2):373

107 Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, Panaccione R, Ghosh S, Wu JCY, Chan FKL (2018) Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of populationbased studies. Lancet 390:2769–2778

108 Ni J,Wu GD, Albenberg L, Tomov VT (2017) Gut microbiota and IBD: causation or correlation? Nat Rev Gastroenterol Hepatol 14:573–584

109 Nishino K, Nishida A, Inoue R, Kawada Y,Ohno M, Sakai S, Inatomi O, Bamba S,Sugimoto M,Kawahara M (2018) Analysis of endoscopic brush samples identified mucosa-associated dysbiosis in inflammatory bowel disease. J Gastroenterol 53:95–106

110 Norman JM, Handley SA, Baldridge MT, Droit L, Liu CY, Keller BC, Kambal A, Monaco CL, Zhao G, Fleshner P (2015) Diseasespecific alterations in the enteric virome in inflammatory bowel disease. Cell 160:447–460

111 Nougayrede JP, Homburg S,Taieb F, Boury M, Brzuszkiewicz E, Gottschalk G, Buchrieser C, Hacker J, Dobrindt U, Oswald E (2006) Escherichia coli induces DNA double-strand breaks in eukaryotic cells. Science 313:848–851

112 Ohkusa T, Sato N, Ogihara T, Morita K, Ogawa M, Okayasu I(2002) Fusobacterium varium localized in the colonic mucosa of patients with ulcerative colitis stimulates species-specific antibody. J Gastroenterol Hepatol 17:849–853

113 Ohkusa T, Okayasu I, Ogihara T, Morita K, Ogawa M, Sato N (2003) Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis. Gut 52:79–83

114 Ohkusa T,Yoshida T, Sato N, Watanabe S, Tajiri H, Okayasu I (2009) Commensal bacteria can enter colonic epithelial cells and induce proinflammatory cytokine secretion: a possible pathogenic mechanism of ulcerative colitis. J Med Microbiol 58:535–545

115 Oliva S, Di Nardo G, Ferrari F,Mallardo S, Rossi P, Patrizi G, Cucchiara S, Stronati L (2012) Randomised clinical trial: the effectiveness of Lactobacillus reuteri ATCC 55730 rectal enema in children with active distal ulcerative colitis. Aliment Pharmacol Ther 35:327–334

116 Ossa JC, Ho NK, Wine E, Leung N, Gray-Owen SD, Sherman PM (2013) Adherent-invasive Escherichia coli blocks interferongamma- induced signal transducer and activator of transcription (STAT)-1 in human intestinal epithelial cells. Cell Microbiol 15:446–457

117 O'Toole PW, Marchesi JR, Hill C (2017) Next-generation probiotics: the spectrum from probiotics to live biotherapeutics. Nat Microbiol 2:17057

118 Owen CD, Tailford LE, Monaco S, Suligoj T,Vaux L, Lallement R, Khedri Z, Yu H, Lecointe K, Walshaw J (2017) Unravelling the specificity and mechanism of sialic acid recognition by the gut symbiont Ruminococcus gnavus. Nat Commun 8:2196

119 Palmela C,Chevarin C, Xu Z, Torres J, Sevrin G, Hirten R,Barnich N, Ng SC, Colombel JF (2018) Adherent-invasive Escherichia coli in inflammatory bowel disease. Gut 67:574–587

120 Paramsothy S, Kamm MA, Kaakoush NO, Walsh AJ, van den Bogaerde J, Samuel D, Leong RWL, Connor S, Ng W, Paramsothy R (2017a) Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebocontrolled trial. Lancet 389:1218–1228

121 Paramsothy S,Paramsothy R, Rubin DT, Kamm MA, Kaakoush NO, Mitchell HM, Castano-Rodriguez N (2017b) Faecal microbiota transplantation for inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis 11:1180–1199

122 Paramsothy S, Nielsen S, Kamm MA, Deshpande NP, Faith JJ, Clemente JC, Paramsothy R, Walsh AJ, van den Bogaerde J, Samuel D (2019) Specific bacteria and metabolites associated with response to fecal microbiota transplantation in patients with ulcerative colitis. Gastroenterology 156:1440–1454. e1442

123 Pittayanon R, Lau JT, Leontiadis GI, Tse F,Yuan Y, Surette M, Moayyedi P(2019) Differences in gut microbiota in patients with vs without inflammatory bowel diseases: a systematic review. Gastroenterology 158(4):930–946.e1

124 Plovier H, Everard A, Druart C,Depommier C, Van Hul M, Geurts L, Chilloux J,Ottman N, Duparc T, Lichtenstein L (2017) A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat Med 23:107–113

125 Png CW, Linden SK, Gilshenan KS, Zoetendal EG, McSweeney CS, Sly LI, McGuckin MA, Florin TH (2010) Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria. Am J Gastroenterol 105:2420–2428

126 Postler TS, Ghosh S(2017) Understanding the holobiont: how microbial metabolites affect human health and shape the immune system. Cell Metab 26:110–130

127 Praveschotinunt P, Duraj-Thatte AM, Gelfat I,Bahl F, Chou DB, Joshi NS (2019) Engineered E. coli Nissle 1917 for the delivery of matrix-tethered therapeutic domains to the gut. Nat Commun 10:5580

128 Prindiville TP, Sheikh RA, Cohen SH, Tang YJ, Cantrell MC, Silva J Jr (2000) Bacteroides fragilis enterotoxin gene sequences in patients with inflammatory bowel disease. Emerg Infect Dis 6:171–174

129 Prorok-Hamon M, Friswell MK, Alswied A, Roberts CL, Song F, Flanagan PK, Knight P,Codling C, Marchesi JR, Winstanley C (2014) Colonic mucosa-associated diffusely adherent afaC+ Escherichia coli expressing lpfA and pks are increased in inflammatory bowel disease and colon cancer. Gut 63:761–770

130 Quevrain E,Maubert MA, Michon C,Chain F, Marquant R, Tailhades J, Miquel S, Carlier L, Bermudez-Humaran LG, Pigneur B (2016) Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn’s disease. Gut 65:415–425

131 Ring C, Klopfleisch R, Dahlke K, Basic M, Bleich A, Blaut M (2019) Akkermansia muciniphila strain ATCC BAA-835 does not promote short-term intestinal inflammation in gnotobiotic interleukin-10-deficient mice. Gut Microbes 10:188–203

132 Rokkas T, Gisbert JP, Niv Y,O’Morain C (2015) The association between Helicobacter pylori infection and inflammatory bowel disease based on meta-analysis. United Eur Gastroenterol J 3:539–550

133 Rossi O, van Berkel LA, Chain F, Tanweer Khan M, Taverne N, Sokol H, Duncan SH, Flint HJ, Harmsen HJ, Langella P(2016) Faecalibacterium prausnitzii A2–165 has a high capacity to induce IL-10 in human and murine dendritic cells and modulates T cell responses. Sci Rep 6:18507

134 Round JL, Lee SM, Li J,Tran G, Jabri B, Chatila TA, Mazmanian SK (2011) The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. Science 332:974–977

135 Sarker SA, Sultana S, Reuteler G, Moine D, Descombes P, Charton F, Bourdin G, McCallin S, Ngom-Bru C, Neville T (2016) Oral phage therapy of acute bacterial diarrhea with two coliphage preparations: a randomized trial in children from Bangladesh. EBioMedicine 4:124–137

136 Sarker SA, Berger B, Deng Y, Kieser S, Foata F, Moine D, Descombes P, Sultana S,Huq S, Bardhan PK(2017) Oral application of Escherichia coli bacteriophage: safety tests in healthy and diarrheal children from Bangladesh. Environ Microbiol 19:237–250

137 Sassone-Corsi M, Nuccio SP, Liu H, Hernandez D,Vu CT, Takahashi AA, Edwards RA, Raffatellu M (2016) Microcins mediate competition among Enterobacteriaceae in the inflamed gut. Nature 540:280–283

138 Scaldaferri F, Gerardi V, Mangiola F,Lopetuso LR, Pizzoferrato M, Petito V, Papa A, Stojanovic J, Poscia A, Cammarota G (2016) Role and mechanisms of action of Escherichia coli Nissle 1917 in the maintenance of remission in ulcerative colitis patients: an update. World J Gastroenterol 22:5505–5511

139 Schirmer M, Garner A, Vlamakis H, Xavier RJ (2019) Microbial genes and pathways in inflammatory bowel disease. Nat Rev Microbiol 17:497–511

140 Schnadower D, Tarr PI, Casper TC, Gorelick MH, Dean JM, O'Connell KJ, Mahajan P, Levine AC, Bhatt SR, Roskind CG (2018) Lactobacillus rhamnosus GG versus placebo for acute gastroenteritis in children. N Engl J Med 379:2002–2014

141 Seishima J,Iida N, Kitamura K, Yutani M, Wang Z, Seki A,Yamashita T, Sakai Y, Honda M, Yamashita T (2019) Gutderived Enterococcus faecium from ulcerative colitis patients promotes colitis in a genetically susceptible mouse host. Genome Biol 20:252

142 Sekizuka T,Ogasawara Y, Ohkusa T,Kuroda M (2017) Characterization of Fusobacterium varium Fv113-g1 isolated from a patient with ulcerative colitis based on complete genome sequence and transcriptome analysis. PLoS ONE 12:e0189319

143 Sepehri S,Khafipour E, Bernstein CN, Coombes BK, Pilar AV, Karmali M, Ziebell K, Krause DO (2011) Characterization of Escherichia coli isolated from gut biopsies of newly diagnosed patients with inflammatory bowel disease. Inflamm Bowel Dis 17:1451–1463

144 Seregin SS, Golovchenko N, Schaf B, Chen J, Pudlo NA, Mitchell J, Baxter NT, Zhao L, Schloss PD, Martens EC (2017) NLRP6 protects Il10(−/−) mice from colitis by limiting colonization of Akkermansia muciniphila. Cell Rep 19:733–745

145 Sinha SR, Haileselassie Y, Nguyen LP, Tropini C, Wang M, Becker LS, Sim D, Jarr K, Spear ET, Singh G (2020) Dysbiosisinduced secondary bile acid deficiency promotes intestinal inflammation. Cell Host Microbe 27(4):659–670.e5

146 Sivignon A, de Vallee A, Barnich N, Denizot J, Darcha C, Pignede G, Vandekerckove P, Darfeuille-Michaud A (2015) Saccharomyces cerevisiae CNCM I-3856 prevents colitis induced by AIEC bacteria in the transgenic mouse model mimicking Crohn’s disease. Inflamm Bowel Dis 21:276–286

147 Sokol H, Pigneur B,Watterlot L, Lakhdari O, Bermúdez-Humarán LG, Gratadoux J-J,Blugeon S,Bridonneau C, Furet J-P, Corthier G (2008a) Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 105:16731–16736

148 Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermudez-Humaran LG, Gratadoux JJ, Blugeon S, Bridonneau C, Furet JP, Corthier G (2008b) Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 105:16731–16736

149 Sokol H, Seksik P, Furet JP, Firmesse O, Nion-Larmurier I, Beaugerie L, Cosnes J, Corthier G, Marteau P, Dore J (2009) Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis 15:1183–1189

150 Sokol H, Leducq V, Aschard H, Pham HP, Jegou S, Landman C, Cohen D, Liguori G, Bourrier A, Nion-Larmurier I (2017) Fungal microbiota dysbiosis in IBD. Gut 66:1039–1048

151 Song X, Sun X, Oh SF, Wu M, Zhang Y,Zheng W,Geva-Zatorsky N, Jupp R, Mathis D, Benoist C (2020) Microbial bile acid metabolites modulate gut RORgamma(+) regulatory T cell homeostasis. Nature 577:410–415

152 Sonnenberg A, Genta RM (2012) Low prevalence of Helicobacter pylori infection among patients with inflammatory bowel disease. Aliment Pharmacol Ther 35:469–476

153 Sonnenborn U (2016) Escherichia coli strain Nissle 1917-from bench to bedside and back: history of a special Escherichia coli strain with probiotic properties. FEMS Microbiol Lett 363(19): fnw212

154 Tailford LE, Owen CD, Walshaw J, Crost EH, Hardy-Goddard J, Le Gall G,de Vos WM, Taylor GL, Juge N(2015) Discovery of intramolecular trans-sialidases in human gut microbiota suggests novel mechanisms of mucosal adaptation. Nat Commun 6:7624

155 Tang C, Kamiya T, Liu Y,Kadoki M, Kakuta S, Oshima K, Hattori M, Takeshita K,Kanai T, Saijo S (2015) Inhibition of Dectin-1 signaling ameliorates colitis by inducing Lactobacillus-mediated regulatory T cell expansion in the intestine. Cell Host Microbe 18:183–197

156 Thiele Orberg E, Fan H, Tam AJ, Dejea CM, Destefano Shields CE, Wu S,Chung L, Finard BB, Wu X, Fathi P (2017) The myeloid immune signature of enterotoxigenic Bacteroides fragilisinduced murine colon tumorigenesis. Mucosal Immunol 10:421–433

157 Tiago FC, Porto BA, Ribeiro NS, Moreira LM, Arantes RM, Vieira AT, Teixeira MM, Generoso SV, Nascimento VN, Martins FS (2015) Effect of Saccharomyces cerevisiae strain UFMG A-905 in experimental model of inflammatory bowel disease. Benef Microbes 6:807–815

158 Underwood AP, Kaakoush NO, Sodhi N,Merif J,Seah Lee W, Riordan SM, Rawlinson WD, Mitchell HM (2016) Campylobacter concisus pathotypes are present at significant levels in patients with gastroenteritis. J Med Microbiol 65:219–226

159 van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JF, Tijssen JG (2013) Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 368:407–415

160 Vich Vila A, Imhann F, Collij V, Jankipersadsing SA, Gurry T, Mujagic Z, Kurilshikov A,Bonder MJ, Jiang X, Tigchelaar EF (2018) Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome. Sci Transl Med 10(472):eaap8914

161 Wagner J, Maksimovic J, Farries G, Sim WH, Bishop RF, Cameron DJ, Catto-Smith AG, Kirkwood CD (2013) Bacteriophages in gut samples from pediatric Crohn’s disease patients: metagenomic analysis using 454 pyrosequencing. Inflamm Bowel Dis 19:1598–1608

162 Wang L, Tang L, Feng Y, Zhao S, Han M, Zhang C, Yuan G, Zhu J, Cao S, Wu Q (2020) A purified membrane protein from Akkermansia muciniphila or the pasteurised bacterium blunts colitis associated tumourigenesis by modulation of CD8(+) Tcells in mice. Gut.https://doi.org/10.1136/gutjnl-2019-320105

163 Wick EC, Rabizadeh S, Albesiano E, Wu X, Wu S, Chan J, Rhee KJ, Ortega G, Huso DL, Pardoll D (2014) Stat3 activation in murine colitis induced by enterotoxigenic Bacteroides fragilis. Inflamm Bowel Dis 20:821–834

164 Wildt S, Nordgaard I, Hansen U, Brockmann E, Rumessen JJ (2011) A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. J Crohns Colitis 5:115–121

165 Williams BB, Van Benschoten AH, Cimermancic P,Donia MS, Zimmermann M, Taketani M, Ishihara A, Kashyap PC, Fraser JS, Fischbach MA (2014) Discovery and characterization of gut microbiota decarboxylases that can produce the neurotransmitter tryptamine. Cell Host Microbe 16:495–503

166 Willing BP, Dicksved J, Halfvarson J, Andersson AF, Lucio M, Zheng Z, Jarnerot G, Tysk C,Jansson JK, Engstrand L (2010) A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterology 139:1844–1854.e1841

167 Wlodarska M, Luo C, Kolde R, d’Hennezel E, Annand JW, Heim CE, Krastel P, Schmitt EK, Omar AS, Creasey EA (2017) Indoleacrylic acid produced by commensal Peptostreptococcus species suppresses inflammation. Cell Host Microbe 22:25–37. e26

168 Xu M, Pokrovskii M, Ding Y, Yi R, Au C, Harrison OJ, Galan C, Belkaid Y, Bonneau R, Littman DR (2018) c-MAF-dependent regulatory T cells mediate immunological tolerance to a gut pathobiont. Nature 554:373–377

169 Yang I,Eibach D, Kops F, Brenneke B, Woltemate S, Schulze J, Bleich A, Gruber AD, Muthupalani S, Fox JG (2013) Intestinal microbiota composition of interleukin-10 deficient C57BL/6J mice and susceptibility to Helicobacter hepaticusinduced colitis. PLoS ONE 8:e70783

170 Yilmaz B, Juillerat P, Oyas O, Ramon C, Bravo FD, Franc Y, Fournier N, Michetti P, Mueller C, Geuking M(2019) Microbial network disturbances in relapsing refractory Crohn’s disease. Nat Med 25:323–336

171 Zamani S, Hesam Shariati S, Zali MR, Asadzadeh Aghdaei HSarabi Asiabar A, Bokaie SNomanpour B, Sechi LA, Feizabadi MM (2017) Detection of enterotoxigenic Bacteroides fragilis in patients with ulcerative colitis. Gut Pathog 9:53

172 Zelante T, Iannitti RG, Cunha C, De Luca A, Giovannini G,Pieraccini G, Zecchi R, D'Angelo C, Massi-Benedetti C, Fallarino F (2013) Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity 39:372–385

173 Zhang L, Man SM, Day AS, Leach ST, Lemberg DA, Dutt S, Stormon M, Otley A, O’Loughlin EV, Magoffin A (2009) Detection and isolation of Campylobacter species other than C. jejuni from children with Crohn’s disease. J Clin Microbiol 47:453–455

174 Zhang FM, Wang HG, Wang M, Cui BT, Fan ZN, Ji GZ (2013) Fecal microbiota transplantation for severe enterocolonic fistulizing Crohn’s disease. World J Gastroenterol 19:7213–7216

175 Zhang L, Lee H, Grimm MC, Riordan SM, Day AS, Lemberg DA (2014) Campylobacter concisus and inflammatory bowel disease. World J Gastroenterol 20:1259–1267

176 Zhu W, Winter MG, Byndloss MX, Spiga L,Duerkop BA, Hughes ER, Buttner L, de Lima Romao E, Behrendt CL, Lopez CA (2018) Precision editing of the gut microbiota ameliorates colitis. Nature 553:208–211

177 Zhu W, Miyata N, Winter MG, Arenales A, Hughes ER, Spiga L, Kim J, Sifuentes-Dominguez L, Starokadomskyy P,Gopal P (2019) Editing of the gut microbiota reduces carcinogenesis in mouse models of colitis-associated colorectal cancer. J Exp Med 216:2378–2393

178 Zuo T, Wong SH, Cheung CP, Lam K, Lui R, Cheung K, Zhang F, Tang W, Ching JYL, Wu JCY (2018) Gut fungal dysbiosis correlates with reduced efficacy of fecal microbiota transplantation in Clostridium difficile infection. Nat Commun 9:3663